# Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia

> **NCT07441876** · PHASE2,PHASE3 · RECRUITING · sponsor: **BioMarin Pharmaceutical** · enrollment: 160 (estimated)

## Conditions studied

- Achondroplasia

## Interventions

- **DRUG:** BMN 333
- **DRUG:** Vosoritide Injection [Voxzogo]

## Key facts

- **NCT ID:** NCT07441876
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2029-06
- **Final completion:** 2029-09
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07441876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07441876, "Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT07441876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*